Addex Therapeutics, Neurosterix, NTX-253, Schizophrenia, Phase 1 Clinical Trial, Phase 2 Development, Muscarinic M4 Receptor, Positive Allosteric Modulator,

GENEVA, Switzerland — October 8, 2026 Addex Therapeutics announced that its spin-out company, Neurosterix, has completed Phase 1 clinical...